Sii’s statement came with a flared background faced after it was told on Wednesday that it would sell one jab from the Covid-19 vaccine of these two doses for ₹ 600 to private facilities and ₹ 400 to the state government.
Indian Serum Institute (SII) on Saturday responded to criticism of the latest price of Covid-19 vaccine, covishield, for state governments and private hospitals, by saying the initial level remains very low globally because it is based on funding funding provided by the state Country for making risky vaccines.
The world’s largest vaccine manufacturer explained that the government’s procurement for immunization programs in all countries, including India, has been at a much lower price because the volume is very large. “There is inaccurate comparisons carried out between the global vaccine price and India. Covishield is the most affordable Covid-19 vaccine available on the market today. The initial price is maintained very low globally because it is based on advanced funding provided by these countries For in the field of risk vaccines. The initial supply price of covishield for all government immunization programs, including India, has become the lowest, “SII said Pune-based in a convincing statement of transparency.
Sii’s statement came with a flared background faced after it was told on Wednesday that it would sell one jab from this two-dose vaccine for ₹ 600 to private facilities and ₹ 400 to the state government as a state preparation for the third phase of vaccination from 1. May , The CEO of the Pharmaceutical Company Adar Poonawalla then said for a new contract, the center must also pay ₹ 400 for each covishield dose, such as the state and UT government, according to a report. However, the early UNI Ministry of Health on Saturday issued a clarification that the center would buy both vaccines at RS150 and the dose will be free to America.
According to the seriousness of the situation during the second wave of the Covid-19 pandemic and the company’s needs to ensure sustainability, SII said, “The current situation is very terrible; this virus continues to mutate while the public remains at risk. Identify uncertainty, we must ensure sustainability because we must be able to invest in improving and expand our capacity to fight pandemics and save lives. ”
Pune-based companies added that only most of the Volume SII would be sold to private hospitals at ₹ 600 per dose and ensured that vaccine costs were still lower than many other medical care and important to treat covid- 19 and other life-threatening diseases.
When the country fights with a second wave of infection,
Adar Poonawalla suggests, it is important for the market to open other vaccines from all over the world. “This will accelerate and advance our country’s immunization program,” he said in the statement.
Sii’s Covishield, which has been developed by the University of Oxford and Astrazeneca, and Covaxin Bharat Biotech is being used in driving large government vaccinations in race against pandemics, which affect millions throughout the country.